1. Draw 2 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming or direct stream onto the powder.
3. Gently swirl or roll until fully dissolved (do not shake).
4. Label with reconstitution date and refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL total, 1 unit = 0.01 mL » 66.7 mcg total (~33.3 mcg of each peptide) on a U-100 insulin syringe.

BPC-157 is a synthetic pentadecapeptide (15 amino acids) originally isolated from human gastric juice. Preclinical research indicates it exerts cytoprotective effects across multiple organ systems, promotes angiogenesis, modulates nitric oxide pathways, and interacts with growth-factor systems involved in tissue repair. TB-500 (Thymosin b4) is a naturally occurring peptide that regulates actin polymerization, promotes cell migration, reduces inflammation, and supports wound healing and tissue regeneration. The combination is hypothesized to provide complementary mechanisms for accelerated musculoskeletal and soft-tissue recovery

• Tissue Repair: Both peptides demonstrate wound-healing, tendon-repair, and anti-inflammatory
  properties in animal models.
• Gastrointestinal Support: BPC-157 shows gastroprotective and ulcer-healing effects in preclinical
  studies.
• Safety Profile: Preclinical data indicate a wide safety margin for BPC-157 (no lethal dose up to ~20
  mg/kg); TB-500 human tolerability studies report mild adverse events at doses up to 1,260 mg.
• Possible Side Effects: Occasional mild injection-site reactions (redness, itching); rare reports of
  transient dizziness or nausea; long-term human safety data remain limited.